X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support the clinical development of COMP360 (psilocybin), which is currently undergoing late-stage clinical trial evaluation for treatment-resistant depression.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Journey Clinical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 29, 2024
Details:
The collaboration aims to inform the delivery model design of investigational COMP360, a proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD).
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hackensack Meridian Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 16, 2024
Details:
The collaboration aims to explore delivery models for investigational COMP360 psilocybin treatment upon regulatory approval by the U.S. Food and Drug Administration.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Greenbrook TMS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2024
Details:
COMP360 (psilocybin) treatment is currently being evaluated in phase 2 clinical trials for the treatment of patients with post-traumatic stress disorder (PTSD).
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
COMP360 psilocybin therapy to help people with treatment-resistant depression (TRD), post-traumatic stress disorder and anorexia nervosa. The phase 3 program consists of two pivotal trials (COMP 005 and COMP 006), and each trial has an integrated, long-term outcomes component.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
The net proceeds will be used to advance the pivotal phase 3 program for COMP360 psilocybin therapy to help people with treatment-resistant depression (TRD), post-traumatic stress disorder and anorexia nervosa.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TCGX
Deal Size: $285.0 million Upfront Cash: $125.0 million
Deal Type: Private Placement August 16, 2023
Details:
The net financing will support company's COMP360, a stabilised, high-purity polymorphic crystalline synthesised formulation of psilocybin, in phase 3 program in treatment-resistant depression (TRD).
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 05, 2023
Details:
COMP360 is stabilised, high-purity polymorphic crystalline synthesised formulation of psilocybin, act on serotonin 2a receptor in brain, believed that acting on this receptor may make brain work with greater flexibility, allowing region to connect and communicate more easily.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Psilocybin (COMP360) therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
The phase II clinical trial will compare the effects of 25 mg and 1 mg of investigational COMP360 psilocybin when administered with psychological support, in 60 participants with anorexia nervosa
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kings College London
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
